Strategic partnerships Opportunity: Leverage NanoVation’s lcLNP platform and commitment to extrahepatic delivery to approach pharma companies with cardiometabolic and rare disease programs, especially those seeking targeted nucleic acid therapies beyond the liver.

Funding signal Opportunity: Engage potential investors and strategic co-development partners following their recent funding and board expansion to explore joint ventures, milestone-driven collaborations, or co-funded programs.

Award momentum Opportunity: Capitalize on the Deal of the Year recognition to approach pharmaceutical companies with proof of market validation, using the award as a credibility boost in negotiations for collaboration or licensing deals.

Key hires Opportunity: Reach out to enterprises seeking government program expertise and global deployment capabilities by offering NanoVation’s potential in patient access programs, regulatory strategy, or international partnerships.

Strategic alignment Opportunity: Target large biotech and pharma players with NVO-like portfolios for co-development of genetic medicines, highlighting lcLNP’s tissue targeting advantages to address unmet needs in rare and cardiometabolic diseases.